SCHEMBL1344147

SCHEMBL1344147

O=C(O)C=Cc1ccc(Cl)c(F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.53
HSD17B10 Q99714 3/20 0.53
MAPK1 P28482 3/20 0.53
CA12 O43570 3/20 0.53
CA1 P00915 3/20 0.53
CA2 P00918 3/20 0.53
CA3 P07451 3/20 0.53
CA4 P22748 3/20 0.53
CA6 P23280 3/20 0.53
CA5A P35218 3/20 0.53
CA7 P43166 3/20 0.53
CA9 Q16790 3/20 0.53
CA14 Q9ULX7 3/20 0.53
CA5B Q9Y2D0 3/20 0.53
AKR1B10 O60218 2/20 0.53
AKR1B1 P15121 2/20 0.53
DPP4 P27487 2/20 0.53
ALDH1A1 P00352 2/20 0.53
HPGD P15428 2/20 0.53
HDAC3 O15379 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1344144 1.00 KDM4E (0.53) KDM4EHSD17B10MAPK1CA12CA1
SCHEMBL13858839 0.86 PYGL (0.45) TDP1PTPN11NR0B2PYGLKCNA3
SCHEMBL1167815 0.86 ITGB2 (0.60) KDM4EHSD17B10MAPK1CA12CA1
SCHEMBL1167812 0.86 ITGB2 (0.60) KDM4EHSD17B10MAPK1CA12CA1
SCHEMBL13858840 0.86 PYGL (0.45) TDP1PTPN11NR0B2PYGLKCNA3
SCHEMBL5388770 0.84 PELI1 (0.44) TDP1PYGLKCNA3
SCHEMBL5479840 0.84 IAPP (0.54) APPGLATDP1PYGLKCNA3
Hydrochloric Acid SCHEMBL6821819 0.84 ITGB2 (0.59) KDM4EHSD17B10MAPK1CA12CA1
SCHEMBL5388767 0.84 PELI1 (0.44) TDP1PYGLKCNA3
SCHEMBL5479835 0.84 IAPP (0.54) APPGLATDP1PYGLKCNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116687903-A Application of cinnamic acid compound prepared from cinnamon active ingredient in preparation of product for inhibiting tyrosinase activity 五邑大学 2023-09-05 CN disclosed
EP-3321262-B1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2021-01-13 EP disclosed
US-10323022-B2 Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-06-18 US disclosed
US-20180334450-A1 PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2018-11-22 US disclosed
EP-3321262-A1 SERINE/THREONINE KINASE INHIBITORS Array Biopharma, Inc. (US) 2018-05-16 EP disclosed
US-20180127393-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2018-05-10 US disclosed
EP-2820009-B1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2018-01-31 EP disclosed
US-9878997-B2 Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors ARRAY BIOPHARMA INC. (US) 2018-01-30 US disclosed
US-20170217936-A1 PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2017-08-03 US disclosed
US-9708290-B2 Serine/threonine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2017-07-18 US disclosed
US-20090023713-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE, INC. 2009-01-22 US disclosed
WO-2009010429-A2 NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-01-22 WO disclosed
EP-2010506-A1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-Roche AG (CH) 2009-01-07 EP disclosed
WO-2007122103-A1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2007-11-01 WO disclosed
US-20070249589-A1 Novel diazepan derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-10-25 US disclosed
US-7247649-B2 Oxazoles, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2007-07-24 US disclosed
EP-1656371-A2 NOVEL OXAZOLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2006-05-17 EP disclosed
WO-2005016921-A2 NOVEL OXAZOLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2005-02-24 WO disclosed
US-20050038091-A1 Novel oxazoles, their manufacture and use as pharmaceutical agents F. HOFFMANN-LA ROCHE AG (CH) 2005-02-17 US disclosed
US-6277502-B1 ORGANOSILICON POLYMERS; LIQUID CRYSALS ROLIC AG (CH) 2001-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10323022-B2 Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors RET, TK1, DSTYK KDM4E 2047/4885HSD17B10 4832/4885MAPK1 126/4885
US-20070249589-A1 Novel diazepan derivatives CCR3, CCR1, CCR10 KDM4E 3080/4885HSD17B10 3681/4885MAPK1 2116/4885
US-20090023713-A1 HETEROCYCLIC COMPOUNDS CCR5, CCR3, CCR2 KDM4E 3545/4885HSD17B10 2652/4885MAPK1 1052/4885
US-20180334450-A1 PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS RET, TK1, DSTYK KDM4E 2047/4885HSD17B10 4832/4885MAPK1 126/4885
US-20180127393-A1 SERINE/THREONINE KINASE INHIBITORS MAP3K1, MAP3K11, TTBK1 KDM4E 3484/4885HSD17B10 2967/4885MAPK1 51/4885
US-20050038091-A1 Novel oxazoles, their manufacture and use as pharmaceutical agents OXA1L, CYP11B2, RORB KDM4E 3949/4885HSD17B10 542/4885MAPK1 2907/4885
US-20170217936-A1 PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS RET, TK1, DSTYK KDM4E 2047/4885HSD17B10 4832/4885MAPK1 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.